公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2024 | Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines | Teng, Wei; Chang, Ting-Tsung; Yang, Hwai-I; Peng, Cheng-Yuan; Su, Chien-Wei; TUNG-HUNG SU ; Hu, Tsung-Hui; Yu, Ming-Lung; Yang, Hung-Chih; Wu, Jaw-Ching | Hepatology international | |||
2021 | Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines | Teng, Wei; Chang, Ting-Tsung; Yang, Hwai-I; Peng, Cheng-Yuan; Su, Chien-Wei; TUNG-HUNG SU ; Hu, Tsung-Hui; Yu, Ming-Lung; HUNG-CHIH YANG ; Wu, Jaw-Ching | Hepatology international | 15 | 11 | |
2021 | Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C | SHIH-JER HSU ; Yu, Ming-Lung; Su, Chien-Wei; Peng, Cheng-Yuan; Chien, Rong-Nan; Lin, Hsien-Hong; Lo, Gin-Ho; Su, Wei-Wen; Kuo, Hsing-Tao; Hsu, Chao-Wei; Yang, Sien-Sing; Yang, Sheng-Shun; Tseng, Kuan-Chiao; Qin, Albert; Huang, Yi-Wen; Chuang, Wan-Long | Journal of the Formosan Medical Association = Taiwan yi zhi | 14 | 12 |